EUVIMEDEUVIMED entdecken
Crossref

Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study

David Sánchez-García iD, Yesica Luna-Garza, Eloísa Saavedra-Castillo, Graciela Gómez-Martínez, Marcelo Diaz-Sallas, Alejandra Claudia Ortega-Valdez, Zinia Fernanda Martínez-Mendoza, Karina Rosa Reyes-Valdez, Rosa Alicia Huitron-Ramirez, Janeth Patricia Martinez-Rentería, Ricardo Rocha-Rojas, Ana Livia Dominguez-Rodriguez und 2 weitere

Diabetic Medicine · 2026-04 · 43 (4)

DOI: 10.1111/dme.70222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 15.02.2026. Verfasst von David Sánchez-García und 13 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Hospital de Especialidades UMAE 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico. Hauptthemen laut MEDLINE: Liraglutide, Diabetes Mellitus, Type 1, Atherosclerosis, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the effect of liraglutide on carotid intima–media thickness (CIMT) and cardiometabolic risk in adults with type 1 diabetes (T1D).

Methods

We conduct a prospective, quasi‐experimental study including adults aged 15–60 years with T1D, suboptimal control and on basal‐bolus insulin regimen. Participants received liraglutide 1.8 mg/day for 24 weeks. Anthropometric measurements, laboratory parameters, insulin sensitivity (estimated glucose disposal rate, eGDR) and CIMT (high‐resolution B‐mode ultrasonography) were assessed at baseline, 12 and 24 weeks. Paired t ‐tests, Wilcoxon‐signed rank tests and McNemar's tests were used for statistical comparisons.

Results

Thirty‐five participants (median age 36 years; 57.1% women) were included. Baseline mean HbA1c was 67 mmol/mol (8.3%), CIMT 0.54 ± 0.13 mm, and median diabetes duration 11 years. After 24 weeks, liraglutide did not significantly modify CIMT (0.54 vs. 0.58 mm; p = 0.151). However, significant improvements were observed in waist circumference (82.5–79 cm; p = 0.004), body weight (70–66.7 kg; p < 0.001), BMI (25.5–24.3 kg/m 2 ; p < 0.001), triglycerides (94–75 mg/dL; p = 0.02) and eGDR (7.9–8.9 mg/kg/min; p = 0.003). HbA1c improved at 12 weeks but was not sustained at week 24. No severe hypoglycaemia, diabetic ketoacidosis, emergency visits or hospitalizations occurred.

Conclusions

In adults with T1D, liraglutide improved several cardiometabolic risk factors and insulin sensitivity, although no significant short‐term effects on CIMT were observed. Larger long‐term trials are needed to clarify its potential role in cardiovascular prevention in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideDiabetes Mellitus, Type 1AtherosclerosisHypoglycemic AgentsHumansAdultFemalePilot ProjectsMaleProspective StudiesCarotid Intima-Media ThicknessMiddle AgedAdolescentYoung AdultCardiometabolic Risk FactorsGlycated HemoglobinBlood Glucose

Stichwörter der Autor:innen

GLP‐1 receptor agonistcardiovascular riskcarotid intima–media thicknessliraglutidesubclinical atherosclerosistype 1 diabetes

Substanzen

LiraglutideHypoglycemic AgentsGlycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Endocrinology Department, Hospital de Especialidades UMAE 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico.
  • Hospital Christus Muguerza Sur, Centro Médico, Monterrey, Mexico.

ORCID-Profile: David Sánchez-García

Zitieren

APA

Sánchez-García, D., Luna-Garza, Y., Saavedra-Castillo, E., Gómez-Martínez, G., Diaz-Sallas, M., Ortega-Valdez, A. C., Martínez-Mendoza, Z. F., Reyes-Valdez, K. R., Huitron-Ramirez, R. A., Martinez-Rentería, J. P., Rocha-Rojas, R., Dominguez-Rodriguez, A. L., Garza-Davila, K. D., & Quintanilla-Flores, D. L. (2026). Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study. Diabetic Medicine, 43(4). https://doi.org/10.1111/dme.70222

Vancouver

Sánchez-García D, Luna-Garza Y, Saavedra-Castillo E, Gómez-Martínez G, Diaz-Sallas M, Ortega-Valdez AC, et al. Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study. Diabetic Medicine. 2026;43(4). doi:10.1111/dme.70222

BibTeX
@article{SnchezGarca2026,
  author = {Sánchez-García, David and Luna-Garza, Yesica and Saavedra-Castillo, Eloísa and Gómez-Martínez, Graciela and Diaz-Sallas, Marcelo and Ortega-Valdez, Alejandra Claudia and Martínez-Mendoza, Zinia Fernanda and Reyes-Valdez, Karina Rosa and Huitron-Ramirez, Rosa Alicia and Martinez-Rentería, Janeth Patricia and Rocha-Rojas, Ricardo and Dominguez-Rodriguez, Ana Livia and Garza-Davila, Kelly Danara and Quintanilla-Flores, Dania Lizet},
  title = {Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study},
  journal = {Diabetic Medicine},
  year = {2026},
  volume = {43},
  number = {4},
  doi = {10.1111/dme.70222}
}
Kostenlos starten →